Form 4 for INBX Inhibrx Biosciences, Inc.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0002007919-24-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-08-22 | 2024-08-20+ | INBX | Lappe Mark | CEO, Dir | P - Purchase | $12.96 | +40.0K | 54.9K | +269% | +$518.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-20 | P | A | 27,055 | $12.97 | 41,920 | I The Mark Paul Lappe Roth IRA | — | — | (F1) The shares were purchased in multiple transactions at prices ranging from $12.77 to $13.14, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
| 2 | Common | Common Stock | 2024-08-21 | P | A | 12,945 | $12.93 | 54,865 | I The Mark Paul Lappe Roth IRA | — | — | (F2) The shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |